Literature DB >> 6577010

Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80.

M Salzer-Kuntschik, G Delling, G Beron, R Sigmund.   

Abstract

The histologic grade of regression of 50 osteosarcomas after polychemotherapy - according to the protocol study, COSS 80 - was classified on a six-stage regression scale; 56% of all patients responded well to chemotherapy regression grades I, II, and III and no significant difference between BCD- and CPL-treated patients could be found. Tumors under 10 cm in length responded better to chemotherapy than those of greater length and there was a good correlation between the clinical estimation of tumor regression and progression and the histologic grade of regression.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6577010     DOI： 10.1007/bf00625047

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  9 in total

1.  [Simplified metacrylate embedding method for undecalcified bone sections].

Authors:  G Delling
Journal:  Beitr Pathol       Date:  1972

2.  [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors].

Authors:  M Salzer-Kuntschik; G Brand; G Delling
Journal:  Pathologe       Date:  1983-05       Impact factor: 1.011

3.  Surgical treatment in the COSS 80 study.

Authors:  R Kotz; W Becker; M Immenkamp
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

4.  Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma.

Authors:  G Rosen; M L Murphy; A G Huvos; M Gutierrez; R C Marcove
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

5.  [Osteosarcoma 1978 a turning point in prognosis through adjuvant chemotherapy following adequate surgery (author's transl)].

Authors:  R Kotz
Journal:  Wien Klin Wochenschr Suppl       Date:  1978

6.  Morphological changes in osteosarcoma after chemotherapy--COSS 80.

Authors:  G Delling; H Krumme; M Salzer-Kuntschik
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

8.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

9.  Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study.

Authors:  K Winkler; G Beron; R Kotz; M Salzer-Kuntschik; J Beck; W Beck; W Brandeis; W Ebell; R Erttmann; U Göbel; W Havers; G Henze; L Hinderfield; P Höcker; A Jobke; H Jürgens; H Kabisch; G Landbeck; P Preusser; G Prindull; W Ramach; J Ritter; J Sekera; J Treuner; G Wüst
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553
  9 in total
  60 in total

1.  [Primary malignant bone tumors].

Authors:  R von Eisenhart-Rothe; A Toepfer; M Salzmann; J Schauwecker; H Gollwitzer; H Rechl
Journal:  Orthopade       Date:  2011-12       Impact factor: 1.087

2.  [Isolated limb perfusion for liposarcoma : Histopathological response and subgroup analysis after TNF melphalan-based ILP].

Authors:  L E Podleska; B Schwindenhammer; F Grabellus; S Bauer; H-U Steinau; G Taeger
Journal:  Chirurg       Date:  2017-05       Impact factor: 0.955

3.  [New morphologic findings in malignant bone tumors].

Authors:  G Delling
Journal:  Langenbecks Arch Chir       Date:  1987

4.  Morphological changes in osteosarcoma after chemotherapy--COSS 80.

Authors:  G Delling; H Krumme; M Salzer-Kuntschik
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

5.  [Chemotherapy-induced changes in high grade central osteosarcomas-experiences gained through the assignment as reference-pathologists of the COSS-studies].

Authors:  M Werner; G Delling
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

6.  [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.

Authors:  Douglas S Hawkins; Ernest U Conrad; James E Butrynski; Scott M Schuetze; Janet F Eary
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

7.  [Therapy-induced tumor regression in adult soft tissue sarcomas-morphological findings].

Authors:  C Kuhnen; K-M Müller; H U Steinau; M Lehnhardt
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

Review 8.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

10.  mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis.

Authors:  Quan Zhou; Zhansheng Deng; Yong Zhu; Haitao Long; Shaoxian Zhang; Jiali Zhao
Journal:  Med Oncol       Date:  2009-11-20       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.